TICKERNERD
Menu
DNADNAHealthcare · Biotechnology

DNA Stock Forecast: Ginkgo Bioworks Holdings, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$11
−1.13% on the day

The 3 Wall Street analysts covering Ginkgo Bioworks Holdings, Inc. hold a median 12-month price target of $7 — -38.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 8 Oct 2026 — in the lower half.

Market cap
$763.6M
Ticker Nerd rank
38 / 100
Median analyst target
$7.00
Analysts covering
3
Revenue$20.2M−59.4% y/y
Operating income−$58.5M
Net income−$46.7M
Free cash flow−$46.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.3%
1M
+63.4%
YTD
+36.5%
1Y
−29.5%
From 52W high
−29.5%
From 52W low
+106.9%
$5
$16
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DNA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ginkgo Bioworks Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
85
Issuance
61
Quality
50
Size
48
Revisions
48
Value
37
Growth
36
Momentum
28
Volatility
17

Accruals (85): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (17): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DNA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DNA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4$6$8$10$12$14$16Jan 26Apr 26Jul 26Oct 26DNAHigh $9.00Median $7.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
0 Buy1 Hold2 Sell
Low $5.00Median $7.00High $9.00

The green dot is the last close — the median target sits −38.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 Sept 2026BTIGReiteratesSell$5.00
7 Aug 2026TD CowenDowngradeHold$12 → $9.00
7 Aug 2026TD CowenDowngradeHold—
12 Mar 2026BTIGMaintainsSell$9.00 → $5.00
12 Mar 2026BTIGMaintainsSell—
8 Jan 2026TD CowenMaintainsBuy—
25 Aug 2025BTIGMaintainsSell—
20 Sept 2024TD CowenMaintainsBuy—
23 Aug 2024BTIGMaintainsSell—
9 July 2024Goldman SachsMaintainsSell—
26 June 2024BTIGMaintainsSell—
15 May 2024BTIGDowngradeSell—
15 May 2024Morgan StanleyMaintainsEqual-Weight—
10 May 2024William BlairDowngradeUnderperform—
1 Mar 2024TD CowenMaintainsOutperform—
23 Jan 2024Goldman SachsMaintainsSell—
22 Jan 2024Goldman SachsMaintainsSell—
15 Nov 2023Raymond JamesDowngradeMarket Perform—
14 Nov 2023Raymond JamesDowngradeMarket Perform—
9 Nov 2023BTIGDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DNA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

DNA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Ginkgo Bioworks Holdings, Inc. returned −29.5% against +16.2% for the S&P 500, dividends included.

DNA vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26DNAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DNA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Ginkgo Bioworks Holdings, Inc. (DNA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.0×

Cheaper than 86% of US stocks

Price / sales
5.8×

Cheaper than 22% of US stocks

Price / book
1.7×

Cheaper than 49% of US stocks

EV / EBITDA
−3.3×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
−48.5%

Higher than 6% of US stocks

Earnings growth (YoY)
−59.4%

Higher than 9% of US stocks

Gross margin
91.5%

Higher than 97% of US stocks

Operating margin
−285.0%

Higher than 9% of US stocks

Net margin
−219.6%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−59.9%

Higher than 19% of US stocks

Return on assets
−16.7%

Higher than 22% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Ginkgo Bioworks Holdings, Inc. (DNA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ginkgo Bioworks Holdings, Inc. has a market value of $763.6M and an enterprise value of $874.3M.

  • Revenue in the twelve months to 30 June 2026: $111.9M. The latest quarter shrank 48.5% year on year.

  • Net income over the same four quarters: −$290.8M, a −260.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$174.8M.

  • Shares outstanding: 63.7M.

  • Trailing P/E: −2.0×; forward P/E: −3.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Ginkgo Bioworks Holdings, Inc. employs 485 people — $231K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

DNA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DNAGinkgo Bioworks Holdings, Inc.$763.6M
38
ACHVAchieve Life Sciences, Inc.$738.1M
30
ATTOAttovia Therapeutics, Inc.$743.4M
0
SLDBSolid Biosciences, Inc.$717.0M
44
GYREGyre Therapeutics, Inc.$753.7M
45
OBXObsidian Therapeutics, Inc.$755.5M
59
VSTMVerastem, Inc.$712.3M
59

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ginkgo Bioworks Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DNA news & analysis

Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program

Business Wire · 8 Oct 2026positive

Ginkgo Bioworks announced it will provide in-kind access to its Boston autonomous laboratory for researchers in the National Science Foundation’s X-Labs program. The support includes cloud lab time and protein testing services for the $1.5 billion, decade-long initiative.

Why it matters — The announcement highlights Ginkgo’s contribution of laboratory access and services to a major NSF research program.

This Small-Cap Stock Announced a Deal With Eli Lilly. Then Its Shares Doubled

The Motley Fool · 5 Oct 2026positive

Ginkgo Bioworks and Eli Lilly announced a partnership last month focused on AI drug discovery. Following the announcement, Ginkgo's stock has surged, with shares doubling.

Why it matters — A partnership with a major pharmaceutical company like Eli Lilly in AI drug discovery could be a significant development for Ginkgo's business and investor sentiment, as reflected in the sharp stock price increase.

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know

Zacks Investment Research · 1 Oct 2026negative

Ginkgo Bioworks Holdings, Inc. (DNA) closed the recent trading day at $12.5, representing a -2.57% decline from the preceding trading session, even as the broader market saw an uptick. The stock's decline occurred against a generally rising market backdrop.

Why it matters — The decline stands out because DNA fell while the broader market moved up, indicating company-specific weakness that watchers would want to track.

FAQ

Frequently asked questions about DNA stock

What is the DNA stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Ginkgo Bioworks Holdings, Inc. have a median 12-month price target of $7, with estimates ranging from $5 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DNA stock a buy right now?

Of the 3 analysts covering Ginkgo Bioworks Holdings, Inc., 0 rate it a Buy, 1 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Ginkgo Bioworks Holdings, Inc. 38 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DNA?

As at 8 Oct 2026, Ginkgo Bioworks Holdings, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (85 of 100).

Will DNA stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies -38.3% from the last close, and Ticker Nerd's factor model ranks Ginkgo Bioworks Holdings, Inc. 38 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DNA stock forecast for 2030?

No analyst covering Ginkgo Bioworks Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $9 over the next 12 months.

How has DNA stock performed over the past year?

Ginkgo Bioworks Holdings, Inc. returned -29.5% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ginkgo Bioworks Holdings, Inc. do?

Ginkgo Bioworks Holdings, Inc. Class A Common Stock represents ownership in Ginkgo Bioworks Holdings, a biotechnology company focused on cell engineering and biological design.

What is the latest news on DNA?

The most recent item we track (Business Wire, 8 Oct 2026): "Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program". Ginkgo Bioworks announced it will provide in-kind access to its Boston autonomous laboratory for researchers in the National Science Foundation’s X-Labs program. The support includes cloud lab time and protein testing services for the $1.5 billion, decade-long initiative.

Company

About Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. Class A Common Stock represents ownership in Ginkgo Bioworks Holdings, a biotechnology company focused on cell engineering and biological design. Ginkgo Bioworks develops a platform that helps customers design, build, and test custom microbes and other biological systems for use in industries such as pharmaceuticals, agriculture, food, industrial chemicals, and specialty materials. The company provides biological R&D services, automation-enabled laboratory tools, and data-driven software that support the research, development, and commercialization of engineered organisms. It also serves government and commercial clients through biosecurity-related offerings that support biological monitoring and surveillance. Headquartered in Boston, Massachusetts, Ginkgo Bioworks plays a specialized role in the life sciences market by supplying infrastructure and services that make biological engineering more accessible across multiple sectors.

CEO Dr. Jason Kelly Ph.D. · 485 employees · United States · https://www.ginkgo.bio